# FDA WARNING_LETTER - 24HrDoc, Inc. dba 24HrDoc - December 31, 2025

Source: https://www.keypedia.com/records/warning_letter/24hrdoc-inc-dba-24hrdoc/b4fdaa8e-0948-4cb0-b285-ec078126cf83

> FDA WARNING_LETTER for 24HrDoc, Inc. dba 24HrDoc on December 31, 2025. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: WARNING_LETTER
- Company Name: 24HrDoc, Inc. dba 24HrDoc
- Inspection Date: 2025-12-31
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Summary: The FDA issued a Warning Letter to 24HrDoc, Inc. dba 24HrDoc on February 20, 2026, following a December 2025 review of its website. The letter identified significant violations concerning compounded drug products, specifically semaglutide and tirzepatide. The primary issues involve misbranding under the Federal Food, Drug, and Cosmetic Act (FDCA). 24HrDoc"s website falsely implied it was the compounder of these drugs by displaying "24HrDoc" on product labels. Additionally, the company made misleading claims such as "Same ingredients as: Ozempic and Wegovy" and "Same ingredients as: Mounjaro and Zepbound," suggesting FDA approval or evaluation for safety and effectiveness, which is not true for compounded drugs. These actions violate FDCA sections 502(a) and 502(bb) regarding false or misleading labeling and advertising, and section 301(a) for introducing misbranded products into interstate commerce. 24HrDoc is required to take immediate corrective action. Within 15 working days, they must provide a written response detailing steps taken to address violations, including identifying actual compounders, providing labeling samples, and modifying or removing all false or misleading website claims. Failure to comply could lead to further legal action.

## Related Officers

- [Acting Director](https://www.keypedia.com/people/matthew-j-lash/17e9ae5c-4e10-4aab-91a5-f78f74b99902)

Company: https://www.keypedia.com/companies/24hrdoc-inc-dba-24hrdoc/08a2d805-fc44-4ddf-b837-ae98639703c6

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c